B
PRVB

Bailard’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Bailard’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-41,400
Closed -$434K – 774
2021
Q1 		$434K Buy
41,400
+17,000
+70% +$239K 0.02% 423
2020
Q4 		$413K Hold
24,400
– – 0.02% 367
2020
Q3 		$313K Hold
24,400
– – 0.02% 380
2020
Q2 		$344K Sell
24,400
-18,000
-42% -$227K 0.02% 336
2020
Q1 		$390K Sell
42,400
-7,900
-16% -$102K 0.03% 267
2019
Q4 		$749K Sell
50,300
-5,000
-9% -$44.6K 0.04% 221
2019
Q3 		$377K Buy
55,300
+15,101
+38% +$153K 0.02% 348
2019
Q2 		$486K Buy
+40,199
New +$219K 0.03% 291

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bailard's PRVB Position: Q2 2021 in Review

Bailard sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2021, closing a stake of 41,400 shares — an estimated $434K sold.

Bailard first reported a position in PRVB in Q2 2019 and held it in 8 quarters. The position peaked at $749K in Q4 2019. 125 funds tracked by Wall St. Rank hold PRVB as of Q2 2021.

  • Bailard reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bailard sold 41,400 Provention Bio, Inc. Common Stock shares in Q2 2021, an estimated $434K.
  • Bailard first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Bailard's Provention Bio, Inc. Common Stock position peaked at $749K in Q4 2019.
  • 125 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2021.

Based on Bailard's 13F filing for Q2 2021, filed 13 Aug 2021.